A key component of FDA’s enforcement strategy in the cosmetics space is monitoring companies’ websites for overreaching product claims and issuing warning letters accordingly. Examination of past offenders’ current sites and updated claims offers potential visibility into language the agency will and will not tolerate when it comes to promoting skin-care benefits.
Both FDA and companies typically are cagey about discussing the behind-the-scenes exchanges that take place between the agency and recipients to resolve warning letters.
However, a look at the websites of brands that have been served with warning letters for unapproved drug claims on...